Tandem Diabetes Care Inc. (NASDAQ:TNDM) shares were up 5.6% on Wednesday . The stock traded as high as $8.25 and last traded at $8.13, with a volume of 130,112 shares traded. The stock had previously closed at $7.70.

Several research analysts have recently weighed in on TNDM shares. Bank of America Corp. cut shares of Tandem Diabetes Care from a “neutral” rating to an “underperform” rating in a research note on Thursday, March 24th. Wedbush reiterated an “outperform” rating and set a $20.00 price target on shares of Tandem Diabetes Care in a research note on Wednesday, June 15th. Sterne Agee CRT reiterated a “neutral” rating on shares of Tandem Diabetes Care in a research note on Monday, May 16th. Piper Jaffray Cos. reiterated a “buy” rating and set a $12.00 price target on shares of Tandem Diabetes Care in a research note on Thursday, April 21st. Finally, Zacks Investment Research cut shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. Tandem Diabetes Care currently has a consensus rating of “Buy” and a consensus price target of $14.21.

The stock’s market cap is $239.77 million. The firm’s 50-day moving average price is $7.50 and its 200-day moving average price is $8.33.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Thursday, April 28th. The medical device company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.01. The firm had revenue of $20.06 million for the quarter, compared to the consensus estimate of $17.67 million. The company’s revenue was up 63.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.83) EPS. On average, equities analysts expect that Tandem Diabetes Care Inc. will post ($2.16) earnings per share for the current year.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.